Values as of: 2024-09-18
COMMON STOCK | Biotechnology |
Last Closing
USD 1.3094Change
+0.00 (+0.03)%Market Cap
USD 5.46BVolume
200.00Analyst Target
N/AVerdict
Verdict
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Company Website : https://www.wuxibiologics.com
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| NOVA:F | Novo Nordisk A/S |
-0.50 (-0.42%) |
USD 547.87B |
| NOV:F | Novo Nordisk A/S |
-1.44 (-1.20%) |
USD 547.87B |
| RGO:F | Regeneron Pharmaceuticals Inc |
-1.50 (-0.15%) |
USD 114.77B |
| CSJ:F | CSL Limited |
-1.18 (-0.66%) |
USD 88.37B |
| CSJA:F | CSL LTD SPON.ADR 2 |
-0.50 (-0.56%) |
USD 87.08B |
| UNC0:F | UCB S.A. UNSP.ADR 1/2 |
-3.00 (-3.68%) |
USD 30.35B |
| DUL:F | Alnylam Pharmaceuticals Inc |
+4.20 (+1.74%) |
USD 30.08B |
| 1AEA:F | argenx SE |
-14.00 (-2.93%) |
USD 29.03B |
| 1AE:F | Argen-X |
-14.70 (-3.05%) |
USD 28.94B |
| 22UA:F | BioNTech SE |
-7.60 (-6.75%) |
USD 26.15B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| FID | First Trust Intl Multi-As.. | 1.86 % | 0.69 % |
-0.04 (0.00%) |
USD 0.08B |
| IFGL | iShares International Dev.. | 0.53 % | 0.48 % |
-0.26 (0.00%) |
USD 0.11B |
| SCZ | iShares MSCI EAFE Small-C.. | 0.08 % | 0.39 % |
-0.08 (0.00%) |
USD 9.12B |
| DVYA | iShares Asia/Pacific Divi.. | 0.00 % | 0.49 % |
-0.14 (0.00%) |
N/A |
| EWH | iShares MSCI Hong Kong ET.. | 0.00 % | 0.48 % |
-0.10 (0.00%) |
N/A |
| FGD | First Trust Dow Jones Glo.. | 0.00 % | 0.58 % |
N/A |
N/A |
| 3110:HK | Global X Hang Seng High D.. | 0.00 % | 0.00 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -60.98% | 14% | F | 6% | D- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -60.98% | 14% | F | 6% | D- | ||
| Trailing 12 Months | |||||||
| Capital Gain | -73.59% | 12% | F | 5% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -73.59% | 12% | F | 5% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -27.96% | 12% | F | 5% | F | ||
| Dividend Return | -27.96% | 12% | F | 5% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 34.61% | 47% | F | 35% | F | ||
| Risk Adjusted Return | -80.77% | 9% | A- | 4% | F | ||
| Market Capitalization | 5.46B | 93% | A | 80% | B- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
